Avinash N Mukkala1, Jason Kwan2, Rachel Lau3, David Harris4,5, Dylan Kain4, Andrea K Boggild6,7,8,9. 1. University of Toronto, Institute of Medical Sciences, Toronto, Canada. 2. McMaster University, Hamilton, Canada. 3. Public Health Ontario Laboratories, Public Health Ontario, Toronto, Canada. 4. Department of Medicine, University of Toronto, Toronto, Canada. 5. Tropical Disease Unit, Division of Infectious Diseases, University Health Network-Toronto General Hospital, 200 Elizabeth Street, Room 13EN-218, Toronto, ON, M5G 2C4, Canada. 6. University of Toronto, Institute of Medical Sciences, Toronto, Canada. andrea.boggild@utoronto.ca. 7. Public Health Ontario Laboratories, Public Health Ontario, Toronto, Canada. andrea.boggild@utoronto.ca. 8. Department of Medicine, University of Toronto, Toronto, Canada. andrea.boggild@utoronto.ca. 9. Tropical Disease Unit, Division of Infectious Diseases, University Health Network-Toronto General Hospital, 200 Elizabeth Street, Room 13EN-218, Toronto, ON, M5G 2C4, Canada. andrea.boggild@utoronto.ca.
Abstract
PURPOSE OF REVIEW: Modern advances in malaria rapid diagnostic test (RDT) technology have increased demand for low-cost, easy-to-use assays in areas endemic for malaria. Substantial developments in diagnostic sensitivity and specificity, improvements in non-falciparum RDTs, and novel biotechnological innovations are gradually aligning the performance of RDTs with reference-level diagnostics including PCR and expert microscopy gold standards. RECENT FINDINGS: Trends have emerged in recent malaria RDT literature: (1) improvements in the sensitivity and specificity of RDTs for Plasmodium falciparum diagnosis, making them comparable to expert microscopic examination; (2) reduced false-positive and false-negative reactions with novel antibody development; (3) improved sensitivity and specificity capabilities of Plasmodium vivax-specific RDTs; (4) developing RDTs for co-endemic mixed infection differentiation; (5) significant improvements of RDTs for Plasmodium knowlesi; (6) a global push towards assessing and confronting the growing concerns of widespread pfhrp2 gene deletions; and (7) original innovation in loop-mediated isothermal amplification (LAMP) biotechnological RDT-like platforms that demonstrate promising performance characteristics for P. falciparum, P. vivax, and P. knowlesi infections. The past 5 years have been characterized by increasing demand for malaria RDTs, translating into meaningful improvements in performance and novel biotechnological innovation. Future work should facilitate the development of improved RDT platforms for Plasmodium ovale, P. knowlesi, and Plasmodium malariae, and surmount the issue of pfhrp2 gene deletions, while maintaining comparable performance to both PCR and expert microscopy reference standards.
PURPOSE OF REVIEW: Modern advances in malaria rapid diagnostic test (RDT) technology have increased demand for low-cost, easy-to-use assays in areas endemic for malaria. Substantial developments in diagnostic sensitivity and specificity, improvements in non-falciparum RDTs, and novel biotechnological innovations are gradually aligning the performance of RDTs with reference-level diagnostics including PCR and expert microscopy gold standards. RECENT FINDINGS: Trends have emerged in recent malaria RDT literature: (1) improvements in the sensitivity and specificity of RDTs for Plasmodium falciparum diagnosis, making them comparable to expert microscopic examination; (2) reduced false-positive and false-negative reactions with novel antibody development; (3) improved sensitivity and specificity capabilities of Plasmodium vivax-specific RDTs; (4) developing RDTs for co-endemic mixed infection differentiation; (5) significant improvements of RDTs for Plasmodium knowlesi; (6) a global push towards assessing and confronting the growing concerns of widespread pfhrp2 gene deletions; and (7) original innovation in loop-mediated isothermal amplification (LAMP) biotechnological RDT-like platforms that demonstrate promising performance characteristics for P. falciparum, P. vivax, and P. knowlesiinfections. The past 5 years have been characterized by increasing demand for malaria RDTs, translating into meaningful improvements in performance and novel biotechnological innovation. Future work should facilitate the development of improved RDT platforms for Plasmodium ovale, P. knowlesi, and Plasmodium malariae, and surmount the issue of pfhrp2 gene deletions, while maintaining comparable performance to both PCR and expert microscopy reference standards.
Authors: Matthew J Grigg; Timothy William; Bridget E Barber; Uma Parameswaran; Elspeth Bird; Kim Piera; Ammar Aziz; Prabakaran Dhanaraj; Tsin W Yeo; Nicholas M Anstey Journal: J Clin Microbiol Date: 2014-04-02 Impact factor: 5.948
Authors: Rajeev K Mehlotra; Rosalind E Howes; Estee Y Cramer; Riley E Tedrow; Tovonahary A Rakotomanga; Stéphanie Ramboarina; Arsène C Ratsimbasoa; Peter A Zimmerman Journal: Am J Trop Med Hyg Date: 2019-05 Impact factor: 2.345
Authors: Eric Rogier; Karen E S Hamre; Vena Joseph; Mateusz M Plucinski; Jacquelin Presume; Ithamare Romilus; Gina Mondelus; Tamara Elisme; Lotus van den Hoogen; Jean Frantz Lemoine; Chris Drakeley; Ruth A Ashton; Michelle A Chang; Alexandre Existe; Jacques Boncy; Gillian Stresman; Thomas Druetz; Thomas P Eisele Journal: J Infect Dis Date: 2020-02-18 Impact factor: 5.226
Authors: Emily N Reichert; Jen C C Hume; Issaka Sagara; Sara A Healy; Mahamadoun H Assadou; Merepen A Guindo; Rebecca Barney; Andy Rashid; Ihn Kyung Yang; Allison Golden; Gonzalo J Domingo; Patrick E Duffy; Hannah C Slater Journal: Malar J Date: 2020-09-03 Impact factor: 2.979
Authors: Sam L Nsobya; Andrew Walakira; Elizabeth Namirembe; Moses Kiggundu; Joaniter I Nankabirwa; Emmanuel Ruhamyankaka; Emmanuel Arinaitwe; Melissa D Conrad; Moses R Kamya; Grant Dorsey; Philip J Rosenthal Journal: Malar J Date: 2021-01-02 Impact factor: 2.979